Linked Life Data

17583131

Source:http://linkedlifedata.com/resource/pubmed/id/17583131

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2007-6-22
pubmed:abstractText
Cutaneous lymphoma is a heterogenous entity regarding clinical and pathological features, evolutive profiles and prognosis, molecular abnormalities and response to therapy. Recent classification is based on these specificities, giving a major concern to the prognostic implications of these different entities. While treatment is effective and prognosis is favorable in low grade forms, recent therapeutic innovations relying on the use of biological tools are likely to improve the prognosis of the most severe ones, as it is the case for anti-CD20 monoclonal antibodies (rituximab) in disseminated cutaneous B-cell lymphomas, and anti-CD52 monoclonal antibody (alemtuzumab) in refractory forms of cutaneous T-cell lymphoma. The deciphering of key molecular mechanisms underlying these malignancies should open new therapeutic perspectives in a close future.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0035-2640
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
57
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
469-75
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Cutaneous lymphomas].
pubmed:affiliation
Service de dermatologie 1 et unité Inserm U697, hôpital Saint-Louis, 75475 Paris. herve.bachelez@sls.aphp.fr
pubmed:publicationType
Journal Article, English Abstract, Review